Ibrutinib is under clinical development by AbbVie and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Ibrutinib’s likelihood of approval (LoA) and phase transition for Metastatic Adenocarcinoma of The Pancreas took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ibrutinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Ibrutinib (Imbruvica) is an anti-neoplastic agent. It is formulated as hard gelatin capsules, tablets, film coated tablets and suspension for oral route of administration. Ibrutinib is indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) with 17p deletion and for the treatment of patients with Waldenström’s macroglobulinemia (WM). It is also indicated for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL), chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutationin patients unsuitable for chemo-immunotherapy, Waldenstrom’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy, for the treatment of small lymphocytic lymphoma (SLL), as a first-line treatment for patients with chronic lymphocytic leukemia (CLL), for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion. Imbruvica is now approved for all patients with CLL, expanding the number of patients who may benefit from this treatment. Imbruvica as a single-agent targeted therapy for previously untreated patients with active chronic lymphocytic leukemia (CLL), for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy and in combination with obinutuzumab is indicated in adults for the treatment of naive patients with active chronic lymphocytic leukemia (CLL). Imbruvica (ibrutinib) in combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukemia (CLL).
Ibrutinib (PCI-32765) is under development for treatment of Coronavirus disease 2019 (COVID-19) infectious disease caused by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), her2-positive metastatic breast cancer ( third line ), splenic, extranodal and nodal marginal zone lymphoma (MZL), relapsed and refractory classical Hodgkin lymphoma, pediatric and adolescent patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy, B-cell malignancies (including relapsed and refractory chronic lymphocytic leukemia (CLL),mantle cell lymphoma, small lymphocytic lymphoma (SLL), and diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia, untreated Waldenström’s macroglobulinemia (WM), indolent non-Hodgkin lymphoma, treatment-naive, relapsed and refractory follicular lymphoma (FL), hairy cell leukemia, T-cell lymphoma, primary CNS lymphoma, secondary CNS lymphoma, non small cell lung cancer, multiple myeloma (second and third line), relapsed and refractory marginal zone lymphoma, refractory or steroid-dependent graft versus host disease, recurrent head and neck squamous cell carcinoma, metastatic pancreatic adenocarcinoma, renal cell carcinoma, urothelial carcinoma, colorectal cancer, gastric or gastro-esophageal junctional adenocarcinoma, refractory myelodysplastic syndrome, relapsed and refractory acute lymphocytic leukemia (ALL), metastatic melanoma, and glioblastoma multiforme. ibrutinib in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Imbruvica is indicated for the treatment of relapsed/refractory primary macroglobulinemia and lymphoplasmacytic lymphoma.
It was also under development for rheumatoid arthritis and relapsed or refractory precursor B lymphoblastic leukemia (B-ALL), Burkitt lymphoma and systemic mastocytosis.
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
Quick View Ibrutinib LOA Data
|Highest Development Stage|